drugset / Trial / NCT02203760
Pazopanib Vs. Pazopanib Plus Gemcitabine
Phase 2
Active not recruiting
58 enrolled
North Eastern German Society of Gynaecological Oncology
Novartis Pharmaceuticals · collabmedac GmbH · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a prospective, randomized, open-label, multicenter phase II trial in order to determine progression-free survival of patients with refractory or relapsed metastatic uterine leiomyosarcomas or other metastatic uterine tumours.
Timeline
- Start
- 2019-10-16
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Comparator | Pazopanib | Small molecule | 800 mg | Oral |